Asymmetry Capital Management, L.P. 13F annual report

Asymmetry Capital Management, L.P. is an investment fund managing more than $55.8 million ran by Cindy Goldsmith. There are currently 33 companies in Mrs. Goldsmith’s portfolio. The largest investments include Baxter International and BioMarin Pharmaceutical, together worth $7.22 million.

Limited to 30 biggest holdings

$55.8 million Assets Under Management (AUM)

As of 7th October 2020, Asymmetry Capital Management, L.P.’s top holding is 52,192 shares of Baxter International currently worth over $4.36 million and making up 7.8% of the portfolio value. Relative to the number of outstanding shares of Baxter International, Asymmetry Capital Management, L.P. owns more than approximately 0.1% of the company. In addition, the fund holds 33,781 shares of BioMarin Pharmaceutical worth $2.86 million, whose value fell 6.8% in the past six months. The third-largest holding is Centene worth $2.79 million and the next is Guardant Health worth $2.75 million, with 35,236 shares owned.

Currently, Asymmetry Capital Management, L.P.'s portfolio is worth at least $55.8 million. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Asymmetry Capital Management, L.P.

The Asymmetry Capital Management, L.P. office and employees reside in San Francisco, California. According to the last 13-F report filed with the SEC, Cindy Goldsmith serves as the CFO at Asymmetry Capital Management, L.P..

Recent trades

In the most recent 13F filing, Asymmetry Capital Management, L.P. revealed that it had opened a new position in Baxter International and bought 52,192 shares worth $4.36 million. This means they effectively own approximately 0.1% of the company. Baxter International makes up 9.2% of the fund's Health Care sector allocation and has decreased its share price by 8.1% in the past year.

The investment fund also strengthened its position in Tandem Diabetes Care by buying 24,564 additional shares. This makes their stake in Tandem Diabetes Care total 43,559 shares worth $2.6 million. Tandem Diabetes Care soared 115.0% in the past year.

On the other hand, there are companies that Asymmetry Capital Management, L.P. is getting rid of from its portfolio. Asymmetry Capital Management, L.P. closed its position in Global Blood Therapeutics on 12th February 2020. It sold the previously owned 75,011 shares for $3.64 million. Cindy Goldsmith also disclosed a decreased stake in BioMarin Pharmaceutical by 0.3%. This leaves the value of the investment at $2.86 million and 33,781 shares.

One of the smallest hedge funds

The two most similar investment funds to Asymmetry Capital Management, L.P. are Jd Capital Management and Signia Capital Management. They manage $55.7 million and $55.7 million respectively.

Cindy Goldsmith investment strategy

Asymmetry Capital Management, L.P.’s portfolio is diversified across 3 sectors. Currently, their heaviest sector is Health Care — making up 85.4% of the total portfolio value. The fund focuses on investments in the United States as 81.8% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are large-cap stocks. Stocks with a size of more than $10 billion in market cap make up 27% of the total holdings value. On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio. The average market cap of the portfolio companies is close to $26.6 billion.

The complete list of Asymmetry Capital Management, L.P. trades based on 13F SEC filings

These positions were updated on February 12th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security	Shares Owned	Value	Allocation
Baxter International, Inc.	Opened 52,192	$4,364,000	7.82%
Global Blood Therapeutics, Inc.	Closed 75,011	$3,640,000
BioMarin Pharmaceutical, Inc.	31.43% 33,781	$2,856,000	5.12%
Centene Corp.	Opened 44,426	$2,793,000	5.01%
Guardant Health, Inc.	Opened 35,236	$2,753,000	4.93%
Gw Pharmaceuticals -adr	Closed 23,729	$2,730,000
Insmed, Inc.	54.56% 113,875	$2,719,000	4.87%
Mylan NV	Opened 132,855	$2,670,000	4.79%
PTC Therapeutics, Inc.	54.00% 55,408	$2,661,000	4.77%
Tandem Diabetes Care, Inc.	129.32% 43,559	$2,597,000	4.65%
Bio-rad Laboratories-a	12.65% 6,351	$2,350,000	4.21%
DexCom, Inc.	Closed 14,770	$2,204,000
Natera, Inc.	Closed 63,112	$2,070,000
Arena Pharmaceuticals, Inc.	162.34% 42,688	$1,939,000	3.48%
UnitedHealth Group, Inc.	Opened 6,414	$1,886,000	3.38%
Acceleron Pharma, Inc.	Closed 47,453	$1,875,000
Regeneron Pharmaceuticals, Inc.	Opened 4,584	$1,721,000	3.08%
MyoKardia, Inc.	51.94% 23,023	$1,678,000	3.01%
AbbVie, Inc.	Opened 18,921	$1,675,000	3.00%
Amarin Corp Plc -adr	Closed 104,509	$1,584,000
CRISPR Therapeutics AG	Closed 37,141	$1,522,000
Aerie Pharmaceuticals, Inc.	Opened 62,507	$1,511,000	2.71%
Dermira Inc	Opened 81,127	$1,442,000	2.58%
Exicure, Inc.	Opened 500,000	$1,430,000	2.56%
Esperion Therapeutics, Inc.	Opened 22,872	$1,364,000	2.44%
Gilead Sciences, Inc.	61.13% 20,791	$1,351,000	2.42%
Antares Pharma, Inc.	Closed 377,399	$1,262,000
Bristol-myers Squibb-cvr	Opened 415,931	$1,252,000	2.24%
Momenta Pharmaceuticals, Inc.	Opened 62,585	$1,235,000	2.21%
eHealth, Inc.	Opened 15,004	$1,230,000	2.20%
Portola Pharmaceuticals, Inc.	67.11% 49,431	$1,180,000	2.12%
Twist Bioscience Corp.	42.17% 54,334	$1,141,000	2.05%
Verrica Pharmaceuticals, Inc.	Closed 74,301	$1,097,000
ViewRay, Inc.	Opened 256,205	$1,081,000	1.94%
Nucana Plc-adr	2.72% 159,898	$975,000	1.75%
Amicus Therapeutics, Inc.	Opened 98,718	$962,000	1.72%
Ascendis Pharma A/s - Adr	Opened 6,547	$911,000	1.63%
Cytokinetics, Inc.	Opened 85,172	$904,000	1.62%
Mirati Therapeutics, Inc.	Opened 6,950	$896,000	1.61%
Varian Medical Systems, Inc.	Opened 5,934	$843,000	1.51%
Marinus Pharmaceuticals, Inc.	Opened 354,853	$766,000	1.37%
Heron Therapeutics, Inc.	Closed 39,273	$727,000
Apellis Pharmaceuticals, Inc.	Opened 21,380	$655,000	1.17%
Penumbra, Inc.	Closed 2,700	$363,000
No transactions found
Showing first 500 out of 44 holdings